Synonym
Ergoloid Mesylates, Hydergine, Gerimal, Niloric, Redizork, CCK 179, CCK-179, CCK179
IUPAC/Chemical Name
dihydro-ergotoxine, monomethanesulfonate
InChi Key
PBKVEOSEPXMKDN-HJMQKNHVSA-N
InChi Code
InChI=1S/C35H41N5O5.2C32H43N5O5.C31H41N5O5.4CH4O3S/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34;1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20;1-6-18(4)27-29(39)36-12-8-11-25(36)32(41)37(27)30(40)31(42-32,17(2)3)34-28(38)20-13-22-21-9-7-10-23-26(21)19(15-33-23)14-24(22)35(5)16-20;1-16(2)26-28(38)35-11-
SMILES Code
[H][C@@]12[C@](C3=C4C(C2)=CNC4=CC=C3)([H])C[C@@H](C(N[C@@]5(C(C)C)C(N([C@@H](C(C)C)C(N6[C@@]7([H])CCC6)=O)[C@@]7(O)O5)=O)=O)CN1C.[H][C@@]89[C@](C%10=C%11C(C9)=CNC%11=CC=C%10)([H])C[C@@H](C(N[C@@]%12(C(C)C)C(N([C@@H](CC%13=CC=CC=C%13)C(N%14[C@@]%15([H])CCC%14)=O)[C@@]%15(O)O%12)=O)=O)CN8C.[H][C@@]%16%17[C@](C%18=C%19C(C%17)=CNC%19=CC=C%18)([H])C[C@@H](C(N[C@@]%20(C(C)C)C(N([C@@H](CC(C)C)C(N%21[C@@]%22([H])CCC%21)=O)[C@@]%22(O)O%20)=O)=O)CN%16C.[H][C@@]%23%24[C@](C%25=C%26C(C%24)=CNC%26=CC=C%25)([H])C[C@@H](C(N[C@@]%27(C(C)C)C(N([C@]([C@](C)([H])CC)([H])C(N%28[C@@]%29([H])CCC%28)=O)[C@@]%29(O)O%27)=O)=O)CN%23C.OS(C)(=O)=O.OS(C)(=O)=O.OS(C)(=O)=O.OS(C)(=O)=O
Appearance
White to light yellow crystalline powder.
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
0.00
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lu WJ, Huang JD, Lai ML. The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine. J Clin Pharmacol. 2006 Jun;46(6):628-34. PubMed PMID: 16707409.
2: Yu C, Meng J, Chen J, Tang X. Preparation of ergoloid mesylate submicron emulsions for enhancing nasal absorption and reducing nasal ciliotoxicity. Int J Pharm. 2009 Jun 22;375(1-2):16-21. PubMed PMID: 19504748.
3: Chen J, Wang X, Wang J, Liu G, Tang X. Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats. Eur J Pharm Biopharm. 2008 Mar;68(3):694-700. Epub 2007 Sep 12. PubMed PMID: 17945473.
4: Drugs to treat Alzheimer's disease. J Psychosoc Nurs Ment Health Serv. 2013 Apr;51(4):11-2. doi: 10.3928/02793695-20130306-99. PubMed PMID: 23565878.
5: Woodcock BG, Herrmann W, Habedank WD. Co-dergocrine plasma concentrations and blood pressure changes in hypertensive patients during therapy with slow-release co-dergocrine mesylate. Int J Clin Pharmacol Ther Toxicol. 1992 Feb;30(2):63-5. PubMed PMID: 1551748.
6: Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol. 1994 Aug;51(8):787-98. PubMed PMID: 8042927.
7: Boismare F, Streichenberger G. The action of ergot alkaloids (ergotamine and dihydroergotoxin) on the functional effects of cerebral ischemia in the cat. Pharmacology. 1974;12(3):152-9. PubMed PMID: 4216904.
8: Bohard F, Guennoc A, Klein H, Le Borgne Y, Masanes P. [Hydergine in the treatment of chronic psychoses]. Ann Med Psychol (Paris). 1967 Mar;125(3):438-46. French. PubMed PMID: 4964710.
9: Kozuchowska I, Chmurko E, Zawitkowski J. [Effect of sympatholytics on the retinal vascular system]. Klin Oczna. 1974 Jul;44(7):661-6. Polish. PubMed PMID: 4210840.
10: Saletu B, Grünberger J, Linzmayer L, Anderer P. Dose-response studies with co-dergocrine mesylate under hypoxia utilizing EEG mapping and psychometry. Psychopharmacology (Berl). 1992;109(1-2):30-40. PubMed PMID: 1365669.
11: Wadworth AN, Chrisp P. Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging. 1992 May-Jun;2(3):153-73. Review. PubMed PMID: 1606351.
12: Yaya Huamán R, Blasco Olcina R, García Fernández M, Vilches Padilla JJ. [A study of 93 cases of painful shoulder and shoulder-band syndrome treated with hydergine (author's transl)]. Rev Esp Otoneurooftalmol Neurocir. 1975 May-Jun;33(193):131-5. Spanish. PubMed PMID: 56021.
13: Ourgaud AG, Metge P, Cazenave P. [Eutergine and retinal arteriosclerosis]. Bull Soc Ophtalmol Fr. 1975 May-Jun;75(5-6):591-607. French. PubMed PMID: 813835.
14: McConnachie RW. A clinical trial comparing 'Hydergine' with placebo in the treatment of cerebrovascular insufficiency in elderly patients. Curr Med Res Opin. 1973;1(8):463-8. PubMed PMID: 4204090.
15: ORMA EJ. Hydrogenated ergot alkaloids (hydergine) in the treatment of geriatric postural dizziness. Ann Med Intern Fenn. 1956;45(1):39-44. PubMed PMID: 13355071.
16: Guiraud B, David J, Géraud G, Biermé R, Rascol A. Proceedings: Prevention of ischemic cerebro vascular accident: a long term clinical trial with vasodilator and antiaggregating drugs. Thromb Diath Haemorrh. 1975 Sep 30;34(1):343-4. PubMed PMID: 810915.
17: Thibault A. A double-blind evaluation of 'Hydergine' and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home. Curr Med Res Opin. 1974;2(8):482-7. PubMed PMID: 4217240.
18: ORMA H, VANNAS S. Observations on the use of PH 203 and hydergine in some circulatory disturbances of the fundus and vascular retinopathy. Acta Ophthalmol (Copenh). 1958;36(4):734-49. PubMed PMID: 13594388.
19: ORBAN T. [Experiences with panthesin-hydergine (PH 203) and exacthin (ACTH) in disorders of retinal circulation]. Ophthalmologica. 1960 Dec;140:388-400. German. PubMed PMID: 13731101.
20: Gomaa A, Eissa M, El-Gebaley A. The effect of topically applied vasoactive agents and testosterone versus testosterone in the treatment of erectile dysfunction in aged men with low sexual interest. Int J Impot Res. 2001 Apr;13(2):93-9. PubMed PMID: 11426345.
